Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer

Overview

Journal J Exp Pharmacol

Publisher Dove Medical Press

Date 2020 Nov 18

PMID 33204182

Citations 5

Authors

Sarah K Cimino

Cathy Eng

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer is one of the top causes of cancer and cancer-related deaths worldwide. The prognosis of metastatic colorectal cancer is poor and treatment options are limited. Many patients will run out of treatment options before they become medically unfit for therapy. As such, there is a need to expand upon the current understanding of disease biology as well as drug resistance mechanisms in order to create new approaches for therapy. In this review article, we will discuss the mechanistic rationale and clinical data for new drugs and therapeutic combinations under development for metastatic colorectal cancer.

Citing Articles

Diphenyl ditelluride anticancer activity and DNA topoisomerase I poisoning in human colon cancer HCT116 cells.

Juchem A, Trindade C, Bondan da Silva J, da Silva Machado M, Guecheva T, Rocha J Oncotarget. 2023; 14:637-649.

PMID: 37343056 PMC: 10284427. DOI: 10.18632/oncotarget.28465.

Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia.

Xia Y, An J, Li J, Gu W, Zhang Y, Zhao S Bioact Mater. 2022; 21:499-510.

PMID: 36185744 PMC: 9494038. DOI: 10.1016/j.bioactmat.2022.08.032.

Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma Growth.

Chilamakuri R, Rouse D, Agarwal S Pharmaceuticals (Basel). 2022; 15(5).

PMID: 35631350 PMC: 9144399. DOI: 10.3390/ph15050523.

Therapeutic Targets of KRAS in Colorectal Cancer.

Rahman S, Garrel S, Gerber M, Maitra R, Goel S Cancers (Basel). 2021; 13(24).

PMID: 34944853 PMC: 8699097. DOI: 10.3390/cancers13246233.

Mesenchymal Stem Cell-derived Extracellular Vesicles Transmitting MicroRNA-34a-5p Suppress Tumorigenesis of Colorectal Cancer Through c-MYC/DNMT3a/PTEN Axis.

Zhao J, Lin H, Huang K Mol Neurobiol. 2021; 59(1):47-60.

PMID: 34623601 PMC: 8786758. DOI: 10.1007/s12035-021-02431-9.

References

Yap T, OCarrigan B, Penney M, Lim J, Brown J, De Miguel Luken M . Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol. 2020; 38(27):3195-3204. PMC: 7499606. DOI: 10.1200/JCO.19.02404. View

Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S . Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020; 395(10240):1835-1844. DOI: 10.1016/S0140-6736(20)30934-X. View

Riihimaki M, Hemminki A, Sundquist J, Hemminki K . Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016; 6:29765. PMC: 4945942. DOI: 10.1038/srep29765. View

Tabernero J, Yoshino T, Lee Cohn A, Obermannova R, Bodoky G, Garcia-Carbonero R . Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised,.... Lancet Oncol. 2015; 16(5):499-508. DOI: 10.1016/S1470-2045(15)70127-0. View

Xie Y, Chen Y, Fang J . Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020; 5(1):22. PMC: 7082344. DOI: 10.1038/s41392-020-0116-z. View

Schirripa M, Nappo F, Cremolini C, Salvatore L, Rossini D, Bensi M . KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. Clin Colorectal Cancer. 2020; 19(3):219-225. DOI: 10.1016/j.clcc.2020.04.009. View

Bendell J, Javle M, Bekaii-Saab T, Finn R, Wainberg Z, Laheru D . A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer. 2017; 116(5):575-583. PMC: 5344293. DOI: 10.1038/bjc.2017.10. View

Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A . EGFR Blockade Reverts Resistance to KRAS Inhibition in Colorectal Cancer. Cancer Discov. 2020; 10(8):1129-1139. PMC: 7416460. DOI: 10.1158/2159-8290.CD-20-0187. View

Reaper P, Griffiths M, Long J, Charrier J, MacCormick S, Charlton P . Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. 2011; 7(7):428-30. DOI: 10.1038/nchembio.573. View

10.

Weiss G, Jameson G, Von Hoff D, Valsasina B, Davite C, Di Giulio C . Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. Invest New Drugs. 2017; 36(1):85-95. DOI: 10.1007/s10637-017-0491-7. View

11.

Seshacharyulu P, Ponnusamy M, Haridas D, Jain M, Ganti A, Batra S . Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012; 16(1):15-31. PMC: 3291787. DOI: 10.1517/14728222.2011.648617. View

12.

Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjanen S, Syrjanen K . VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res. 2009; 28(6B):3865-70. View

13.

Diaz Jr L, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022; 23(5):659-670. PMC: 9533375. DOI: 10.1016/S1470-2045(22)00197-8. View

14.

Hughes P, Caenepeel S, Wu L . Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. Trends Immunol. 2016; 37(7):462-476. DOI: 10.1016/j.it.2016.04.010. View

15.

Pfeiffer P, Yilmaz M, Moller S, Zitnjak D, Krogh M, Petersen L . TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020; 21(3):412-420. DOI: 10.1016/S1470-2045(19)30827-7. View

16.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

17.

Bylsma L, Gillezeau C, Garawin T, Kelsh M, Fryzek J, Sangare L . Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med. 2019; 9(3):1044-1057. PMC: 6997095. DOI: 10.1002/cam4.2747. View

18.

Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D . NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012; 11(4):1006-16. DOI: 10.1158/1535-7163.MCT-11-0765. View

19.

Hong D, Fakih M, Strickler J, Desai J, Durm G, Shapiro G . KRAS Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020; 383(13):1207-1217. PMC: 7571518. DOI: 10.1056/NEJMoa1917239. View

20.

Gou M, Si H, Zhang Y, Qian N, Wang Z, Shi W . Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study. Sci Rep. 2018; 8(1):4602. PMC: 5854587. DOI: 10.1038/s41598-018-22302-z. View